In-vivo Proton Magnetic Resonance Spectroscopy in Adnexal Lesions

Seong Whi Cho, MD¹,²
Soon Gu Cho, MD¹
Jung Hee Lee, PhD³
Hyung-Jin Kim, MD¹
Myung Kwan Lim, MD¹
Jong Hwa Kim, MD⁴
Chang Hae Suh, MD¹

Objective: To explore the in-vivo 'H- MR spectral features of adnexal lesions and to characterize the spectral patterns of various pathologic entities.

Materials and Methods: Thirty-one patients with surgically and histopathologically confirmed adnexal lesions underwent short echo-time STEAM (stimulated echo acquisition method) 'H- MR spectroscopy, and the results obtained were analysed.

Results: The methylene present in fatty acid chains gave rise to a lipid peak of 1.3 ppm in the 'H- MR spectra of most malignant tumors and benign teratomas. This same peak was not observed, however, in the spectra of benign ovarian epithelial tumors: in a number of these, a peak of 5.2 ppm, due to the presence of the olefine group (-CH=CH-) was noted. The ratios of lipid peak at 1.3 ppm to water peak (lipid/water ratios) varied between disease groups, and in some benign teratomas was characteristically high.

Conclusion: An intense lipid peak at 1.3 ppm is observed in malignant ovarian tumors but not in benign epithelial tumors. 'H- MRS may therefore be helpful in the differential diagnosis of adnexal lesions.

Most adnexal lesions manifest as cystic masses and differential diagnosis on the basis of imaging findings is difficult. Ultrasonography with color Doppler is currently the standard imaging tool for the differential diagnosis of adnexal masses, and although very sensitive in detecting these and sometimes able to indicate malignancy, it is frequently unable to provide images adequate for specific diagnosis. Physical examinations and the CA 125 serum level are helpful in some cases, and CT and MR imaging are increasingly used to evaluate pelvic masses; malignancy can in some cases be predicted, but since tumors can be graded and histologically assessed to only a limited extent, the results are no better than those obtained with ultrasonography (1-6).

Localized in-vivo proton magnetic resonance spectroscopy ('H- MRS) has been shown to provide information about the contents of organic compounds in living tissues, providing details of tumor metabolism that might well assist tumor grading and lead to a better understanding of the biochemical pathways found within a lesion (7-14). As for ovarian tumors, however, the use of 'H- MRS has -because of technical difficulty- been limited to in-vitro studies such as the analysis of aspirated fluid samples (11). The in-vitro 'H- MR spectrum shows significantly different metabolite concentrations between benign and malignant ovarian cysts: in the latter, significantly higher levels of lactate, isoleucine, valine, 3-hydroxybutylic acid, methionine, and alanine are detected. The recent use of short echo-time (TE) 'H- MRS has facilitated the observation of macromolecules and lipids, in addition to small molecules. For lipids to give rise
to a resonance peak that is narrow enough to be detectable by in-vivo 1H- MRS, their fatty acyl chains must have a significant degree of mobility, and such lipids are therefore described as “mobile” (12). In tumors of the brain and uterine cervix, an elevated lipid peak, as demonstrated by 1H- MRS, is thought to be a possible indicator of malignancy (12, 13): in 1H- MR spectra of these tumors, the presence of the methylene group, CH₃, at 1.3 ppm, and the olefine group, -CH=CH-, at 5.2 ppm, is observed in those that are malignant.

In adnexal lesions, the acquisition of a good quality in-vivo 1H- MR spectrum is very difficult because of motion artifacts caused by respiratory and bowel movements. Moreover, 1H- MR spectroscopy using STEAM with short echo-time might be a more difficult and complex process due to its lower signal-to-noise ratio (SNR) during data acquisition and post-processing. The purpose of this study is to explore the in-vivo 1H- MR spectral features of adnexal lesions using short echo-time and to characterize the spectral patterns of various pathologic entities.

**MATERIALS AND METHODS**

**Patients**

Thirty-one patients aged 22-69 (mean ±SD, 40 ±14) years with surgically proven adnexal lesions were included in this study. There were seven primary or secondary malignant ovarian tumors (2 papillary serous cystadenocarcinomas, 1 mucinous cystadenocarcinoma, 1 sarcomatoid carcinoma, and 3 metastatic adenocarcinomas), one borderline malignant mucinous cystic tumor, six benign epithelial tumors (3 mucinous cystadenomas, 1 serous cystadenoma, 1 serous cystadenofibroma, and 1 benign mixed epithelial tumor), eleven benign teratomas, four endometrioses, one ectopic pregnancy, and one case of salpingitis (Table 1). The maximal diameter of the lesions ranged from 4 to 23 cm, which in all cases was greater than the localization voxel for 1H- MRS. Prior to 1H- MRS,

---

**Table 1. In-vivo 1H-MR Spectroscopic and Pathologic Findings of Adnexal Lesions**

| Patient No. | Age(y) | 1H-MR Spectroscopic Findings | Histopathologic Diagnosis |
|------------|--------|-----------------------------|--------------------------|
| 1          | 54     | Yes, No, 0.007              | Papillary serous cystadenocarcinoma |
| 2          | 61     | Yes, No, 0.009              | Papillary serous cystadenocarcinoma |
| 3          | 50     | Yes, No, NA                | Mucinous cystadenocarcinoma |
| 4          | 61     | No, No, NA                 | Sarcomatoid carcinoma |
| 5          | 62     | Yes, No, 0.006             | Metastatic adenocarcinoma |
| 6          | 48     | Yes, No, 0.007             | Metastatic adenocarcinoma |
| 7          | 45     | No, No, NA                 | Metastatic adenocarcinoma |
| 8          | 29     | Yes, No, 0.006             | Borderline malignant mucinous cystic tumor |
| 9          | 57     | No, No, 0.11               | Mucinous cystadenoma |
| 10         | 52     | No, No, NA                 | Mucinous cystadenoma |
| 11         | 28     | No, No, NA                 | Mucinous cystadenoma |
| 12         | 45     | No, No, 0.005              | Serous cystadenoma |
| 13         | 25     | No, No, 0.006              | Serous cystadenofibroma |
| 14         | 25     | No, No, 0.007              | Benign mixed epithelial tumor |
| 15         | 42     | Yes, No, 0.013             | Teratoma |
| 16         | 37     | Yes, No, 0.341             | Teratoma |
| 17         | 29     | Yes, No, 0.005             | Mature cystic teratoma |
| 18         | 39     | Yes, No, 0.061             | Mature cystic teratoma |
| 19         | 22     | Yes, No, 0.071             | Mature cystic teratoma |
| 20         | 31     | Yes, No, 0.273             | Mature cystic teratoma |
| 21         | 23     | Yes, No, 0.319             | Mature cystic teratoma |
| 22         | 36     | No, Yes, 0.005             | Mature cystic teratoma |
| 23         | 52     | No, Yes, 0.008             | Mature cystic teratoma |
| 24         | 25     | No, No, 0.004              | Mature cystic teratoma |
| 25         | 36     | No, No, 0.007              | Mature cystic teratoma |
| 26         | 25     | No, Yes, 0.006             | Endometriosis |
| 27         | 40     | No, Yes, 0.007             | Endometriosis |
| 28         | 30     | No, No, 0.004              | Endometriosis |
| 29         | 24     | No, No, 0.006              | Endometriosis |
| 30         | 69     | Yes, No, 0.010             | Acute and chronic salpingitis with necrosis |
| 31         | 44     | No, Yes, 0.010             | Ectopic Pregnancy |

Note. — NA= not available
pelvic CT and/or MRI was performed in all patients, none of whom has undergone treatment or biopsy.

**MR Spectroscopy**

For *in-vivo* $^1$H- MRS, a 1.5-T whole-body GE MRI/MRS system (Signa Horizon; General Electric Medical Systems, Milwaukee, Wis., U.S.A.) equipped with active shielded gradients was used. Prior to $^1$H- MRS, pelvic CT or MRI findings were reviewed by a radiologist to determine the location of adnexal lesions. MR imaging using a fast multiplanar spoiled gradient-echo (FMPSPGR) sequence (TR/TE= 100/1.5, NEX=1, matrix size=256×128, slice thickness=8.0 mm, interslice gap=2.0 mm) was performed in which the localization voxel was placed on the adnexal lesion. Voxel size was approximately 8 cm$^3$ (2×2×2 cm), and the voxel was located safely within the lesion in order to reduce contamination from adjacent normal tissue. For all spectra, a STEAM (stimulated echo acquisition method) localization sequence combined with a three-pulse CHESS (chemical shift selective sequence) to suppress the H$_2$O signal was used, and the acquisition parameters were as follows: TR=3000 ms, TE=30 ms, number of scans=128, and number of excitations=1. During spectroscopic signal acquisition, the subjects respired quietly without interruption. Respiratory gating was not used in this study.

**Spectral Analysis and Statistical Methods**

Post-processing involving the use of a SUN SPARC 20 workstation with Spectral Analysis/General Electric (SA/GE) software; incorporated in this were low-frequency filtering of residual water signal, apodization by 0.5 Hz of exponential line broadening, zero-filling of 8000, Fourier transformation, and lorentzian-to-gaussian transformation.

$^1$H- MR spectra both with and without water-peak suppression were obtained, and all spectra were analysed with particular attention to the presence of lipid peaks at 1.3 and 5.2 ppm, and a water peak at 4.77 ppm. Lipid/water ratios were calculated by integrating the peak area of the

---

Fig. 1. Patient 2. Mucinous cystadenocarcinoma in a 61-year old woman. (A) Gadolinium-enhanced axial MR image and (B) axial scanogram obtained using $^1$H- MRS reveal a cystic tumor with a solid nodular component. A prominent lipid peak occurred at about 1.3 ppm in (C) water-unsuppressed and (D) water-suppressed spectra, and the calculated lipid-to-water ratio was 0.009.
lipid peak at 1.3 ppm and water peaks in water-unsuppressed spectra. In spectra that demonstrated a dominant lipid peak at about 1.3 ppm, the highest peak point ±0.3 ppm of both the lipid and water peak was integrated. In 1H-MR spectra that showed no dominant lipid peak, a range of 1.0-1.6 ppm was integrated in order to determine lipid content. The chi-square test was used to analyse spectroscopic data, and difference rankings between means at a statistically significant level were thus established. A p value of 0.05 was considered statistically significant.

RESULTS

A resonance peak at 1.3 ppm, caused by the presence of the methylene group in fatty acid chains, was observed in five of the seven malignant ovarian tumors and seven of the eleven benign teratomas (Figs. 1, 4), as well as in one borderline malignant tumor and the case of salpingitis (Fig. 2). Interestingly, whereas most primary and secondary malignant ovarian tumors showed an intense lipid peak at 1.3 ppm, this same peak was not observed in the MR spectra of any of the six benign ovarian epithelial tumors (Fig. 3). Thus, the incidence of a lipid peak was significantly higher in malignant tumors than in benign epithelial tumors (p < 0.05). A lipid peak at 5.2 ppm, due to the presence of the olefine group in fatty acid chains, was observed in two cases of the eleven benign teratomas, one of the four endometrioses, and the ectopic pregnancy. The 1H-MR spectra of benign ovarian epithelial tumors showed no detectable lipid peak at 1.3 or 5.2 ppm (Tables 1, 2).

The lipid/water ratio was determined in 26 cases and was smaller than 0.020 in 21 of these. The lipid/water ratios of benign teratomas showed great variation, and some were higher than those of other adnexal lesions. In addition, all five cases in which the lipid/water ratio was greater than 0.020 were benign teratomas (p < 0.05).

Fig. 2. Patient 8. Borderline malignant mucinous cystic tumor in a 29-year-old woman. (A) Pelvic post-contrast CT scan and (B) axial scanogram obtained using 1H-MRS show a large multisepated cystic mass with nodular enhancing peripheral portions. A prominent lipid peak was noted at 1.3 ppm in (C) water-unsuppressed and (D) water-suppressed spectra, and the lipid-to-water ratio was 0.006.
DISCUSSION

In our study, $^1$H- MR spectroscopic patterns differed markedly according to the histopathologic diagnosis of the adnexal lesions. In fatty acid chains, the presence of the methylene group caused a resonance peak at 1.3 ppm in most patients with malignant ovarian tumors, benign teratomas and salpingitis. However, no lipid peak at 1.3 ppm was found in the $^1$H- MR spectra of benign ovarian epithelial tumors or endometrioses.

In many previous studies involving in-vivo and ex-vivo MRS of brain tumors and uterine cervical carcinomas, the resonance peak due to fatty acid chains has been suggested as a possible cancer marker (12-14); the results of our study also support this possibility. Interestingly, Gotsis et al. (14) reported that $^1$H- MRS demonstrated the presence of lipids in malignant brain tumors, abscesses and epidermoid cysts, but not in benign brain tumors. They assumed that necrosis and lipid formation might be the result of tumor proliferation without a neovascular network sufficient for its metabolic needs. Kuesel et al. (12) used ex-vivo

| Histopathologic Diagnosis | No. of Cases Showing Peaks at MRS | Lipid/Water Ratio at 1.3 ppm | Lipid/Water Ratio at 5.2 ppm |
|---------------------------|----------------------------------|-----------------------------|-----------------------------|
| Malignant tumor           | 5/7*                             | 0.007 ± 0.001†              |                             |
| Borderline malignant tumor| 1/1                              | 0.006                       |                             |
| Benign epithelial tumor   | 0/6*                             | 0.007 ± 0.002†              |                             |
| Endometriosis             | 0/4                              | 0.006 ± 0.001†              |                             |
| Benign teratoma           | 7/11*                            | 0.101 ± 0.138†              |                             |
| Salpingitis               | 1/1                              | 0.010                       |                             |
| Ectopic pregnancy         | 0/1                              | 0.010                       |                             |

Note. — *statistical significance ($p < 0.05$), as determined by the chi-square test; †mean ± 1 standard deviation

Fig. 3. Patient 11. Mucinous cystadenoma in a 28-year-old woman. (A) Post-contrast CT scan and (B) axial scanogram obtained using $^1$H- MRS demonstrate a large multiseptated cystic pelvic mass. There was no prominent lipid peak at 1.3 ppm in either (C) water-unsuppressed or (D) water-suppressed spectra, and the lipid-to-water ratio was unavailable.
$^1$H- MRS to evaluate mobile lipid resonance at biopsy or in surgical specimens of cerebral astrocytomas, discovering that in high-grade tumors, $^1$H- MRS is able to detect high lipid levels. Rapid cellular turnover in malignant tissue usually leads to considerable cellular death, resulting in cellular necrosis, which appears in in-vivo $^1$H- MR spectra as a lipid signal. This was previously observed in a study of human cervical carcinoma using in-vivo $^1$H- MRS; invasive cervical carcinoma could be differentiated from normal cervix by a peak at 1.3 ppm, with 89% sensitivity and 57% specificity (13). In our study, a $^1$H- MR spectral peak at 1.3 ppm was detected in malignant or borderline malignant ovarian tumors, with 75% sensitivity (6/8) and 65% specificity (15/23).

Because the T2 values of fatty acids and macromolecules are very short, $^1$H- MRS using a short TE is required for the detection of these molecules. Owing to overlap in the spectral peaks demonstrated by macromolecules and lipids, the peaks obtained with short TE values (< 40 msec) are not as well resolved as those obtained with TE values greater than 90 msec (15-17). To avoid overlap between a lipid peak and one due to other metabolites at 1.3 ppm, the peak at 5.3 ppm caused by the presence of olefine has sometimes been used to identify the lipid component of a tumor (12). However, it can be assumed that because the baseline of the spectrum is relatively flat, the peaks occurring at about 1.3 ppm in the short TE MR spectrum of the human ovary are due mainly to the presence in fatty acid chains of the methylene group, and possibly lactate, but not macromolecules. According to a report by Massuger et al. (11), in-vitro $^1$H- NMR studies of ovarian cystic fluids have disclosed that the amount of metabolites such as lactate, methionine, pyruvic acid, and 3-hydroxybutylic acid found in malignant cysts was over six times greater than in

---

**Fig. 4. Patient 21.** Benign mature cystic teratoma in a 23-year-old woman. (A) Transaxial T1-weighted (TR/TE=483/9) image and (B) axial scanogram obtained using $^1$H- MRS show a large pelvic mass with a heterogeneous internal texture. The focal, bright, high signal intensity of the tumor indicates its fat component. A very prominent lipid peak at about 1.3 ppm in (C) water-unsuppressed and (D) water-suppressed spectra was apparent, and the lipid-to-water ratio was 0.319.
benign cysts. In our study, however, the only MR spectral difference between benign and malignant ovarian tumors was the lipid peak at 1.3 ppm. Numerous metabolites, including amino acids, fatty acids, and other small molecules are found in ovarian cysts, but due to their limited concentration (i.e. sensitivity) and intrinsic properties such as T1 and T2 relaxation times, in-vivo 1H-MRS was able to detect only a limited variety. Thus, in our study, we assumed that the peaks occurring at 1.3 ppm were due mainly to a tumor’s lipid component. Evidence which also supported our assumption was the occurrence of a prominent peak at 1.3 ppm in most benign mature cystic teratomas in our study.

The combination of long- and short-TE spectra may be useful for evaluating the presence within a tumor of metabolites, lipids, and macromolecules (18). In studies of brain and uterine cervical tumors, 1H-MRS using long TE has been used to detect long-T2 lipid components: nonmalignant cells of normal lipids have a short T2 value and are thus apparent only in the spectrum of short TE. Lipid components in a malignant tumor, on the other hand, assumed to have a long T2 (> 400 msec), can be detected by long-TE 1H-MRS (13, 14, 19). The lipid peak thus detected is therefore attributed to malignant ovarian tissues with long T2 values, and this may indeed imply that the 1H-MR spectroscopic technique is sensitive to early cellular change. In the case of pelvic MRS examination, signal intensity is affected by motion artifact caused by respiratory and peristaltic bowel movement; an NMR study reported that the high susceptibility of the volume localization sequence to motion was a major disadvantage of short-TE STEAM 1H-MRS (20). Hence we used both short- and long-TE MRS at the beginning of this study, but found that the waveforms of long-TE MR spectra were very irregular and non-informative, probably due to artifact. Long- and short-TE MRS data could not be combined, and only short-TE MR spectra could be analysed.

Only a few studies using 1H-MRS have tried to differentiate between ovarian tumors and other pelvic lesions (11, 13, 21). In order to avoid the broad disturbing spectral resonances caused by protein protons, Massuger et al. (11) recently analysed in-vitro 1H-NMR data of deproteinized ovarian cyst fluid samples. The in-vitro 1H-NMR spectra obtained showed significant differences in metabolite concentrations between benign and malignant ovarian cysts, and significantly higher levels of lactate, isoleucine, valine, 3-hydroxybutyric acid, methionine and alanine were detected in malignant epithelial ovarian cysts. According to them, the elevated metabolite level and branched-chain amino acids found in malignant ovarian tumors most likely result from anaerobic glycolysis and enhanced proteolysis.

In our study, however, these peaks were not usually detected by in-vivo 1H-MR spectroscopy because the minimal concentration detectable by 1.5-T MR instruments is currently tens of millimoles.

Although various lesions in our study demonstrated a lipid peak at 1.3 ppm, the lipid/water ratio was useful to differentiate ovarian lesions. As they can be diagnosed easily by the detection of a lipid component at CT or MRI, teratomas demonstrated characterize greater lipid/water ratios than other ovarian lesions; all our five cases in which the lipid/water ratio was greater than 0.020 were teratomas.

This study has several limitations, one of which is that 1H- MR spectroscopic and radiologic findings were not compared. Another is the small number of cases studied. In order to establish indications of in-vivo 1H- MR spectroscopic diagnosis, further investigation involving a large number of cases is required.

In conclusion, various ovarian lesions can be distinguished by careful disclosure of in-vivo 1H-MR spectra, and in-vivo 1H-MRS is potentially able to discriminate between malignant and benign tumors. The presence of a lipid peak at 1.3 ppm is a useful indicator of malignancy.

References

1. Granberg S, Norstrom A, Wikland M. Tumors in the lower pelvis as imaged by vaginal sonography. Gynecol Oncol 1990; 37:224-229
2. Levine D, Feldstein VA, Babcook CJ, Filly RA. Sonography of brain and uterine cervical tumors, 1H-MRS using long TE has been used to detect long-T2 lipid components: nonmalignant cells of normal lipids have a short T2 value and are thus apparent only in the spectrum of short TE. Lipid components in a malignant tumor, on the other hand, assumed to have a long T2 (> 400 msec), can be detected by long-TE 1H-MRS (13, 14, 19). The lipid peak thus detected is therefore attributed to malignant ovarian tissues with long T2 values, and this may indeed imply that the 1H-MR spectroscopic technique is sensitive to early cellular change. In the case of pelvic MRS examination, signal intensity is influenced by motion artifact caused by respiratory and peristaltic bowel movement; an NMR study reported that the high susceptibility of the volume localization sequence to motion was a major disadvantage of short-TE STEAM 1H-MRS (20). Hence we used both short- and long-TE MRS at the beginning of this study, but found that the waveforms of long-TE MR spectra were very irregular and non-informative, probably due to artifact. Long- and short-TE MRS data could not be combined, and only short-TE MR spectra could be analysed.

Only a few studies using 1H-MRS have tried to differentiate between ovarian tumors and other pelvic lesions (11, 13, 21). In order to avoid the broad disturbing spectral resonances caused by protein protons, Massuger et al. (11) recently analysed in-vitro 1H-NMR data of deproteinized ovarian cyst fluid samples. The in-vitro 1H-NMR spectra obtained showed significant differences in metabolite concentrations between benign and malignant ovarian cysts, and significantly higher levels of lactate, isoleucine, valine, 3-hydroxybutyric acid, methionine and alanine were detected in malignant epithelial ovarian cysts. According to them, the elevated metabolite level and branched-chain amino acids found in malignant ovarian tumors most likely result from anaerobic glycolysis and enhanced proteolysis.

In our study, however, these peaks were not usually detected by in-vivo 1H-MR spectroscopy because the minimal concentration detectable by 1.5-T MR instruments is currently tens of millimoles.

Although various lesions in our study demonstrated a lipid peak at 1.3 ppm, the lipid/water ratio was useful to differentiate ovarian lesions. As they can be diagnosed easily by the detection of a lipid component at CT or MRI, teratomas demonstrated characterize greater lipid/water ratios than other ovarian lesions; all our five cases in which the lipid/water ratio was greater than 0.020 were teratomas.

This study has several limitations, one of which is that 1H- MR spectroscopic and radiologic findings were not compared. Another is the small number of cases studied. In order to establish indications of in-vivo 1H- MR spectroscopic diagnosis, further investigation involving a large number of cases is required.

In conclusion, various ovarian lesions can be distinguished by careful disclosure of in-vivo 1H-MR spectra, and in-vivo 1H-MRS is potentially able to discriminate between malignant and benign tumors. The presence of a lipid peak at 1.3 ppm is a useful indicator of malignancy.

References

1. Granberg S, Norstrom A, Wikland M. Tumors in the lower pelvis as imaged by vaginal sonography. Gynecol Oncol 1990; 37:224-229
2. Levine D, Feldstein VA, Babcook CJ, Filly RA. Sonography of brain and uterine cervical tumors, 1H-MRS using long TE has been used to detect long-T2 lipid components: nonmalignant cells of normal lipids have a short T2 value and are thus apparent only in the spectrum of short TE. Lipid components in a malignant tumor, on the other hand, assumed to have a long T2 (> 400 msec), can be detected by long-TE 1H-MRS (13, 14, 19). The lipid peak thus detected is therefore attributed to malignant ovarian tissues with long T2 values, and this may indeed imply that the 1H-MR spectroscopic technique is sensitive to early cellular change. In the case of pelvic MRS examination, signal intensity is influenced by motion artifact caused by respiratory and peristaltic bowel movement; an NMR study reported that the high susceptibility of the volume localization sequence to motion was a major disadvantage of short-TE STEAM 1H-MRS (20). Hence we used both short- and long-TE MRS at the beginning of this study, but found that the waveforms of long-TE MR spectra were very irregular and non-informative, probably due to artifact. Long- and short-TE MRS data could not be combined, and only short-TE MR spectra could be analysed.

Only a few studies using 1H-MRS have tried to differentiate between ovarian tumors and other pelvic lesions (11, 13, 21). In order to avoid the broad disturbing spectral resonances caused by protein protons, Massuger et al. (11) recently analysed in-vitro 1H-NMR data of deproteinized ovarian cyst fluid samples. The in-vitro 1H-NMR spectra obtained showed significant differences in metabolite concentrations between benign and malignant ovarian cysts, and significantly higher levels of lactate, isoleucine, valine, 3-hydroxybutyric acid, methionine and alanine were detected in malignant epithelial ovarian cysts. According to them, the elevated metabolite level and branched-chain amino acids found in malignant ovarian tumors most likely result from anaerobic glycolysis and enhanced proteolysis.
criminate benign from malignant ovarian tumors. *Cancer* 1998;82(9):1726-1730

12. Kuesel AC, Briere KM, Halliday WC, Sutherland GR, Donnelly SM, Smith ICP. Mobile lipid accumulation in necrotic tissue of high-grade astrocytomas. *Anticancer Research* 1996;16:1485-1490

13. Lee JH, Cho KS, Kim Y-M, et al. Localized in-vivo ¹H nuclear MR spectroscopy for evaluation of human uterine cervical carcinoma. *AJR* 1998; 170:1279-1282

14. Gotsis ED, Fountas K, Kapsalaki E, Toulas P, Peristeris G, Papadakis N. In-vivo proton MR spectroscopy: the diagnostic possibilities of lipid resonances in brain tumors. *Anticancer Research* 1996;16:1565-1568

15. Behar KL, Rothman DL, Spencer DD, Petroff OAC. Analysis of macromolecule resonances in ¹H NMR spectra of human brain. *Magn Reson Med* 1994;32:294-302

16. Hwang J-H, Graham GD, Behar KL, Alger JR, Prichard JW, Rothman DL. Short echo time proton magnetic resonance spectroscopic imaging of macromolecule and metabolic signal intensities in the human brain. *Magn Reson Med* 1996;35:633-639

17. Posse S, Schuknecht B, Smith ME, van Zijl PCM, Herschkovitz N, Moonen CTW. Short echo time proton MR spectroscopic imaging. *J Comput Assist Tomogr* 1994;17:1-14

18. Hwang J-H, Egnaczyk GF, Ballard E, Dunn RS, Holland SK, Ball WS Jr. Proton MR spectroscopic characteristics of pediatric pilocytic astrocytomas. *AJNR* 1998;19:535-540

19. Mountfold CE, Saunders JK, May GL, et al. Classification of human tumors by high-resolution magnetic resonance spectroscopy. *Lancet* 1986;1:651-652

20. Moonen CTW, von Kienlin M, van Zijl PCM, et al. Comparison of single shot localization methos (STEAM and PRESS) for in-vivo proton NMR spectroscopy. *NMR Biomed* 1989;2:201-208

21. Schiebler ML, Miyamoto KK, White M, Maygargen SJ, Mohler JL. In vitro high resolution ¹H-spectroscopy of the human prostate: benign prostatic hyperplasia, normal peripheral zone and adenocarcinoma. *Magn Reson Med* 1993;29:285-291